IFITM2 and breast carcinoma: In general, TNFAIP6, IFRD1, IFITM2, IFNGR1, and NFIL3 would be good markers for early diagnosis, since they are all present before the tumor formation in the model; however, IRF6 could be a good marker for tumor development in the patient, which could help to predict the response of the immune system in breast cancer patients.